A client is admitted with a diagnosis of major depression and states, “Nothing brings me pleasure anymore.” Which behaviors will the nurse assess that correlate with the diagnosis?

Choice A reason: A lithium level of 1.2 mEq/L is within the therapeutic range (0.6–1.5 mEq/L) for bipolar disorder. Symptoms like confusion, ataxia, polyuria, and blurred vision indicate toxicity, which occurs at higher levels, typically above 1.5 mEq/L, making this level unlikely for these severe symptoms.

Choice B reason: A lithium level of 1.4 mEq/L is at the upper end of the therapeutic range. While mild side effects may occur, severe symptoms like mental confusion, ataxia, and polyuria suggest toxicity, which typically occurs at levels above 1.5 mEq/L, ruling out this option.

Choice C reason: A lithium level of 2.3 mEq/L indicates toxicity, causing neurological symptoms (confusion, ataxia), polyuria due to nephrogenic diabetes insipidus, and blurred vision from central nervous system effects. These symptoms align with lithium toxicity, which occurs at levels above 1.5 mEq/L, making this the expected level.

Choice D reason: A lithium level of 1.8 mEq/L is slightly above therapeutic range and may cause mild toxicity symptoms, such as tremor or nausea. However, the severe symptoms described (confusion, ataxia, polyuria) are more consistent with higher toxic levels, such as 2.3 mEq/L, making this less likely.

Choice A reason: SSRIs increase serotonin levels in the brain, effectively managing GAD with a low risk of dependence. Side effects like nausea or headache are generally mild and transient, making SSRIs safer compared to other classes, as they do not cause significant physiological dependence or severe adverse effects.

Choice B reason: Tricyclic antidepressants affect multiple neurotransmitters, effectively treating GAD but with significant side effects like anticholinergic effects (dry mouth, constipation) and potential cardiotoxicity. They carry a higher risk of overdose and side effects compared to SSRIs, making them less safe for long-term use in GAD.

Choice C reason: Benzodiazepines enhance GABA activity, providing rapid anxiety relief but with a high risk of physiological dependence and withdrawal. Side effects like sedation and cognitive impairment, along with abuse potential, make them less safe than SSRIs for long-term GAD management.

Choice D reason: MAOIs inhibit monoamine oxidase, increasing neurotransmitter levels for GAD treatment. However, they have significant side effects, including hypertensive crises from dietary tyramine, and require strict dietary restrictions. Their risk profile and potential for severe interactions make them less safe than SSRIs.